Spotlight On... Osiris CEO steps down for 'personal reasons'; AstraZeneca's Soriot up for deals that pay off quickly; Witty balks at breakup talk; and more...

Osiris Therapeutics ($OSIR) CEO Lode Debrabandere is resigning his position after 10 years at the company, citing "personal reasons." Dwayne Montgomery, Osiris' current chief business officer, is taking over on an interim basis, the company said. Debrabandere has served as CEO since 2013 when his predecessor, Randal Mills, resigned for "personal reasons" of his own. The biotech's shares fell more than 10% on Thursday. More

@FierceBiotech: FierceBiotech Radio on Gilead's wide-open future, biotech's long winter and Sanofi's ongoing makeover. More/Subscribe | Follow @FierceBiotech

@JohnCFierce: ICYMI: Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging. Article | Follow @JohnCFierce

> AstraZeneca ($AZN) CEO Pascal Soriot said the company is open to making acquisitions but only for assets that can quickly add value. News

> GlaxoSmithKline ($GSK) CEO Andrew Witty is preaching patience as some analysts call for the company to be split apart. Item

> London hedge fund manager George Robinson is now reaping the benefits of his work helping U.K. biotechs Adaptimmune ($ADAP) and Immunocore off the ground. Story

Medical Device News

@FierceMedDev: Next 'blow up' for Theranos? The company's latest legal hire: NYT. Article | Follow @FierceMedDev

@EmilyWFierce: Come for a story about stem cell therapy in felines. Stay for a pic of Bob the cat. More from FierceAnimalHealth | Follow @EmilyWFierce

> ViaCyte acquires J&J IP to further its quest to treat diabetes using implanted stem cells. Story

> Abbott snags CE mark for continuous glucose monitor for kids. Article

> Dx Digest: Illumina inks four genetic research deals; Trovagene makes moves in liquid biopsy with additional coverage for tests. Report

Pharma News

@FiercePharma: Stem cell therapy developed to treat dental disease in cats could also help people. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Teva is adding 20 jobs at UK plant, but only after cutting 80 as it looks for different skills. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa. Report from FiercePharmaMarketing | Follow @CarlyHFierce

> Media-magnet hearing on Capitol Hill gets underway, with Valeant, Turing under spotlight. News

> Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters. Story

> Patent losses looming, AZ fights back with Brilinta, diabetes and China. Article

CRO News

> Onyx Scientific expands again as GMP demand grows. Article

> Catalent invests more in Asia, beefing up a Singapore supply outpost. More

> Fox Foundation backs Evotec's Parkinson's project. Report

> French CRO Novasep bulks up its manufacturing services in the U.S. Story

> BioClinica launches new research offering for marketed meds. Article

Pharma Manufacturing News

> Pakistani man charged with bringing counterfeit drugs into U.S. Report

> Ipca's small-scale API producer in U.K. expanding. Story

> Sanofi commits to developing Zika vax while other big players will evaluate. Item

> Valeant's Bausch + Lomb recalls more than 1M bottles of eye med. More

> Sanofi says job cuts in France should not involve plant closures. Article

Pharma Asia News

> Japan's Daiichi Sankyo joins clinical trial data request system. News

> Pfizer's busy Q4 in emerging markets a prelude for the big show. More

> BeiGene comes in at top end of range in Nasdaq IPO, raising $158.4M. Report

> Asia included in Zika virus warning zone as drugmakers ponder vaccines. Story

> GSK's CEO says it's 'difficult to understand how company is doing.' Article

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.